newsfilter
← Latest News
GlobeNewswire·

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ:REUN, TSX:REUN) ("Reunion" or "the Company"), a biopharmaceutical company committed to developing innovative and patented therapeutic